NCI launches systematic search for exceptional cancer drug responders using genome sequencing

NCI launches systematic search for exceptional cancer drug responders using genome sequencing The passage describes a research initiative by the National Cancer Institute to re‑examine archived trial data for outlier responders to cancer therapies. While it outlines a potentially valuable scientific approach, it does not implicate high‑level officials, financial misconduct, or controversial actions, and the information is largely already public in the scientific community. Key insights: A patient with 17,136 tumor mutations responded dramatically to everolimus due to TSC1 and NF2 mutations.; Dr. Solit’s team identified similar TSC1 mutations in a few other trial participants.; The NCI is now mining its archives of ~10,000 trial participants to find ~100 exceptional responders.